Completed
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
NCT02230761
- Conditions
- Blepharoptosis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Connective Tissue Diseases, +8 more
- Locations
-
- Topokine Therapeutics Clinical Study Centers Boston, Massachusetts, United States